Prothena's AL Amyloidosis drug finds success in cardiac cohort | $PRTA
Drug companies frequently claim a proprietary compound can treat several different diseases. Prothena Corporation plc (NASDAQ:PRTA) asserts its platform, which targets misfolded proteins, extends to more than 25 diseases. Specifically, the company directs its drugs towards proteins such as amyloid beta (Aβ), tau, alpha-synuclein, light chain and transthyretin.
With amyloid beta and tau as targets, Prothena owns three Alzheimer’s drugs in its pipeline, one of which is partnered with Bristol-Myers Squibb (NASDAQ:BMY). However, the company’s most advanced drug is birtamimab, a monoclonal antibody. Birtamimab is in a potentially registrational phase III trial to treat AL amyloidosis, a rare plasma cell disorder. AL amyloidosis involves the production of a misfolded amyloidogenic light chain by a plasma cell clone that eventually deposits in different organs, including the heart, leading to organ failure. Significantly, Prothena owns all rights to birtamimab while it has partnered marketing rights to its three other leading clinical candidates to three different companies.
Key catalysts
Topline data from phase III trial testing birtamimab to treat AL Amyloidosis with advanced cardiac involvement
Key catalyst dates
4Q 2024 – 1Q 2025
—
